BRD2 and cardiac hypertrophy: These findings thus suggest that inhibition of BRD2 is a potential strategy for treating pathological cardiac hypertrophy, and that the therapeutic potential of pan-BETi in cardiovascular diseases is at least partially attributed to BRD2 inhibition.